Iodinated contrast media exposure and incident hyperthyroidism and hypothyroidism in a community-based cohort

Connie M. Rhee,1,2 Katherine E. Lynch,1,3 Kambiz Zandi-Nejad,4,4 Elizabeth N. Pearce,5 Erik K. Alexander,2,6 Steven M. Brunelli1,2,7
1Renal Division, Department of Medicine, Brigham and Women’s Hospital, Boston, MA; 2Harvard Medical School, Boston, MA; 3Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA; 4Division of Nephrology, Harvard Vanguard Medical Associates, Boston, MA; 5Section of Endocrinology, Diabetes, and Nutrition, Department of Medicine, Boston University School of Medicine, Boston, MA; 6Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women’s Hospital, Boston, MA; 7DaVita Clinical Research, Minneapolis, MN, USA

Abstract

Recent data suggest iodinated contrast media (ICM) exposure is associated with increased risk of incident hyperthyroidism among patients receiving care from two tertiary care medical centers. We sought to conﬁrm and generalize these ﬁndings by conducting a case-control study among a broadly-representative community-based cohort of patients receiving care within Harvard Vanguard Medical Associates from 1996 to 2012. Incident hyperthyroid and hypothyroid cases were deﬁned by change in thyrotropin (TSH) from normal (at baseline), to low or high (at follow-up), respectively. In parallel analyses, hyper- and hypothyroid cases were matched to euthyroid controls using incidence density sampling, and ICM exposure was ascertained using claims data. Secondary analyses examined associations with incident overt hyperthyroidism and overt hypothyroidism (follow-up TSH≤0.1 mIU/L and TSH>10 mIU/L, respectively). We observed that ICM exposure was independently associated with incident hyperthyroidism and incident overt hypothyroidism.5 Patients in that study had care centered at one of two tertiary care centers in the Partners Health Care system. Given that these patients may differ from the general population in terms of socio-demographics and overall health status that may have bearing on the risk of thyroid functional disease, we sought to validate ﬁndings in a more broadly representative population. This study therefore was designed to estimate the association between ICM receipt and incident thyroid functional disease among a contemporary cohort of patients cared for by Harvard Vanguard Medical Associates (HVMA), a large community-based multispecialty group in the New England area.

Materials and Methods

Study cohort

The study protocol was approved by the Partners HealthCare Institutional Review Board. We conducted a nested case-control study using administrative data from HVMA, a large nonprofit multispecialty group practice in New England providing care to 325,000 patients with >3 million ambulatory visits on an annual basis.7 HVMA has an integrated electronic medical record system with comprehensive capture of longitudinal data on socio-demographics, diagnostic and procedural codes, laboratory results, prescription dispensation, ambulatory encounters, and vital status, and has been employed in numerous health services and epidemiologic research studies.8

Patients were included provided that they were age ≥18 years old and met the following criteria: i. Had at least one normal TSH level measured between January 1, 1996 and August 30, 2012 (designated as baseline); ii. Prior to baseline, had no diagnosis of thyroid functional disorder as ascertained by International Classiﬁcation of Diseases, Ninth Revision (ICD-9) diagnostic codes; iii. Prior to baseline, had no laboratory evidence of abnormal thyroid function [thyrotropin (TSH), free thyroxine (FT4), free thyroxine index (FT4I), or total thyroxine (TT4) outside the laboratory assay ref-

Introduction

Iodine is an essential element for thyroid hormone synthesis.1,2 However, in some patients exposure to supraphysiologic levels inhibits thyroid hormone synthesis, resulting in hypothyroidism. Conversely, in other patients high iodide levels provide excess substrate for unregulated thyroid hormone formation, resulting in hyperthyroidism (Jöd Basedow phenomenon). Such phenomena have been observed in response to a variety of exposures including those that confer as little as 300 mcg of iodide.2,3

Iodinated contrast media (ICM) exposure has risen over the past two decades in parallel with increased utilization of contrast-based computed tomography (CT) and cardiac angiography.4 ICM represents a signiﬁcant iodine load: a single dose contains 13,500 µg of free iodide, as well as 15-60 g of bound iodine that may be liberated to free iodide following administration.4,5 The implied iodide load is 90-to-several-hundred-thousand-fold the daily recommended intake for adults (150 mcg). Recently, we reported that ICM was independently associated with incident hyperthyroidism and incident overt hyperthyroidism.5

Correspondence: Connie Rhee, Department of Medicine, Brigham and Women’s Hospital, 75 Francis Street, MRB-4, Boston, 02115 MA, USA. Tel. +1.312.420.8474 - Fax: +1.617.732.6392. E-mail: crhee1@uci.edu

Key words: iodine, contrast, hyperthyroidism, hypothyroidism, Wolf-Chaikoff, Jod Basedow.

Acknowledgements: Harvard Vanguard Medical Associates Arius Health provided access to the data used in these analyses.

Contributions: CMR had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis; CMR, KEL, KZN, ENP, EKA, SMB, study concept and design; CMR, KZN, SMB, acquisition of data; CMR, SMB, analysis and interpretation of data; CMR, SMB, drafting of the manuscript; CMR, KEL, KZN, ENP, EKA, SMB, critical revision of the manuscript for important intellectual content; CMR, SMB, statistical analysis, administrative, technical, or material support; SMB, study supervision.

Funding: this work was supported by grants from the NIH/NIDDK: DK093201 (CMR) and DK079056 (SMB).

Conflict of interests: KZN has received research support from Genzyme, Abbott, and Alexion and has been a consultant/Advisor to Alexion. EKA receives research support from Veracyte, Inc., Asuragen, Inc., and Genzyme, Inc. SMB is now a full-time employee at DaVita Clinical Research. CMR, KL, and ENP have nothing to declare.

Received for publication: 27 June 2013. Accepted for publication: 7 July 2013.

This work is licensed under a Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).

doi:10.4081/es.2013.e8

©Copyright C.M. Rhee et al., 2013 License PAGEPress, Italy

Endocrinology Studies 2013; 3:e8

[Endocrinology Studies 2013; 3:e8]
Given that the baseline TSH was normal for all subjects, case status was ascribed according to the follow-up TSH level. Incident hypothyroidism was defined by follow-up TSH < assay referent range and incident overt hypothyroidism as follow-up TSH > assay referent range. Euthyroid controls were designated as those in whom the TSH remained within assay referent range at follow-up. Due to sparsity of measurements, TT4, FT4, and FT4I levels were not included in the case definition. In secondary analyses, we examined cases of incident overt hypothyroidism (follow-up TSH≤0.1 mIU/L) and incident overt hypothyroidism (follow-up TSH>10 mIU/L) using cut-offs associated with ≤hyperthyroidism (follow-up TSH>0.1 mIU/L) as ascertained by Current Procedural Terminology or ICD-9 procedural codes; vi. Prior to baseline, had no radioactive iodine ablation or surgical thyroidectomy as ascertained by Current Procedural Terminology or ICD-9 procedural codes; vii. Subsequent to baseline, had a TSH measured within 2 weeks to 2 years (designated as follow-up). Criteria 1 to 5 were designated in order to limit consideration to cases of incident functional disease.

Case and control designation

Table 1. Comparison of baseline characteristics between incident hyperthyroid and hypothyroid cases versus controls in the source cohort and the matched analytical cohort.

| Characteristics | Unmatched controls (n=339,046) (n=3822) | Unmatched hyperthyroid cases (n=339,046) (n=3821) | Matched controls (n=15,282) (n=3821) | Matched hyperthyroid cases (n=7001) (n=7000) |
|-----------------|-----------------------------------------|-----------------------------------------------|--------------------------------------|---------------------------------------------|
| Age (mean±SD)   | 52.2±16.4 48.4±16.2 52.2±16.4 55.4±17.5 | 48.5±15.6 48.4±16.2 55.1±16.7 55.4±17.5 | 51.5±16.4 51.5±16.5 55.1±16.7 55.4±17.5 | 51.5±16.4 51.5±16.5 55.1±16.7 55.4±17.5 |
| Female n. (%)   | 233,512 (68.9) 2985 (78.1) 233,512 (68.9) 4971 (71.0) | 2985 (78.1) 2985 (78.1) 4971 (71.0) 4971 (71.0) | 21,553 (77.0) 5389 (77.0) 21,553 (77.0) 5389 (77.0) | 21,553 (77.0) 5389 (77.0) 21,553 (77.0) 5389 (77.0) |
| White n. (%)    | 236,143 (69.7) 2284 (59.8) 236,143 (69.7) 5389 (77.0) | 2284 (59.8) 2284 (59.8) 5389 (77.0) 5389 (77.0) | 22,84 (80.8) 2284 (59.8) 22,84 (80.8) 5389 (77.0) | 22,84 (80.8) 2284 (59.8) 22,84 (80.8) 5389 (77.0) |
| Renal function n. (%)* | 147,170 (43.4) 2004 (52.4) 147,170 (43.4) 3046 (43.5) | 2004 (52.4) 2004 (52.4) 3046 (43.5) 3046 (43.5) | 12,184 (43.5) 2004 (52.4) 12,184 (43.5) 3046 (43.5) | 12,184 (43.5) 2004 (52.4) 12,184 (43.5) 3046 (43.5) |
| Interval baseline/ follow-up TSH | 370 (370) 309 (309) 370 (370) 365 (365) | 316 (316) 309 (309) 366 (365) 365 (365) | 265 (265) 309 (309) 366 (365) 365 (365) | 265 (265) 309 (309) 366 (365) 365 (365) |
| Median (IQR)    | (219-478) (147-451) (219-478) (200-478) | (200-478) (200-478) (200-478) (200-478) | (152-448) (147-451) (201-471) (200-478) | (152-448) (147-451) (201-471) (200-478) |
| Era n. (%)**    | 1990-1994 16,344 (4.8) 439 (11.5) 16,344 (4.8) 465 (6.6) | 1740 (9.1) 439 (11.5) 1740 (9.1) 465 (6.6) | 1740 (9.1) 439 (11.5) 1740 (9.1) 465 (6.6) | 1740 (9.1) 439 (11.5) 1740 (9.1) 465 (6.6) |
| Contrast exposure n. (%) | 2012-2010 87,869 (26.0) 432 (11.3) 87,869 (26.0) 1933 (5.7) | 1933 (5.7) 432 (11.3) 1933 (5.7) 1933 (5.7) | 1933 (5.7) 432 (11.3) 1933 (5.7) 1933 (5.7) | 1933 (5.7) 432 (11.3) 1933 (5.7) 1933 (5.7) |

*ml/min/1.73m² **Based on follow-up TSH date; TSH, thyrotropin; IQR, interquartile.
controls. Incident hyperthyroid cases and controls were well-balanced on baseline covariates (Table 1). In matched analysis, there was a significant association between ICM exposure and incident hyperthyroidism (Figure 1). On secondary analysis, there was a significant association between ICM exposure and incident overt hyperthyroidism in 1122 cases matched to 4488 controls (Figure 1).

Results were qualitatively similar in sensitivity analyses restricted to cases and controls without prior exposure to lithium or amiodarone or other iodine-containing medications. The adjusted ORs (95% CIs) for ICM exposure were 1.65 (1.30-2.10; P<0.001) for incident hyperthyroidism and 1.52 (1.00-2.32; P=0.05) for incident overt hyperthyroidism.

Association between iodinated contrast media exposure and hypothyroidism

Of 7001 eligible cases of incident hyperthyroidism, 7000 cases were matched to 27,981 controls. Hypothyroid cases and controls were well-balanced on baseline covariates (Table 1). In matched analysis, we did not observe a significant association between ICM exposure and incident hypothyroidism (Figure 1). On secondary analysis, we observed a significant association between ICM exposure and incident overt hypothyroidism among 812 cases matched to 3248 controls: OR 2.01 (95% CI 1.25-3.23; P<0.001) for incident overt hypothyroidism and 2.53 (1.51-4.24; P<0.001) for incident overt hyperthyroidism.

Results were qualitatively similar in sensitivity analyses limited to cases and controls without prior exposure to lithium or amiodarone or other iodine-containing medications. The adjusted ORs (95% CIs) for ICM exposure were 1.00 (0.86-1.15; P>0.9) for incident hypothyroidism and 2.53 (1.51-4.24; P<0.001) for incident overt hyperthyroidism.

Discussion

In this study, we observed that there was a significant association between ICM exposure and incident hyperthyroidism within a community-based cohort of ambulatory patients in the New England area. Under normal conditions, free iodide is an essential element for thyroid hormone synthesis. However, it has long been recognized that acute or chronic exposure to excess iodine from non-ICM sources (e.g., medications, disinfectants, diet) may result in thyrotoxicosis in some patients. Iodine-induced hyperthyroidism (Jod Basedow phenomenon) has typically been described in patients with latent nodular or diffuse goiter or Graves’ disease residing in areas of iodine deficiency who remain clinically euthyroid until iodine repletion. However, iodine-induced hyperthyroidism has also been observed in patients without pre-existing thyroid disease residing in iodine-replete regions. Using data from the Partners HealthCare system, we recently reported the first controlled study of ICM-associated thyrotoxicosis amongst 178 and 76 cases with incident hypothyroidism and incident overt hyperthyroidism, respectively, in an iodine-sufficient region in Boston. However, given that this preliminary study considered patients whose care was centered at tertiary centers and who were also sociodemographically homogenous, generalizability of findings to community-based populations, particularly those with greater racial/ethnic diversity, had been uncertain. We thus sought to examine these associations within a large, community-based cohort whose health status was more representative of the broader population. We again observed a significant association between ICM exposure with incident hyperthyroidism and overt hyperthyroidism, corroborating earlier findings. These collective data bear great clinical relevance given the known adverse effects of hyperthyroidism on multiple organ systems (e.g., bone, neuropsychiatric) particularly the cardiovascular system (e.g., atrial fibrillation, high-output heart failure, angina, and possibly greater cardiovascular mortality). Although untested, it has been suggested that prophylactic treatment with methimazole or perchlorate may be warranted in high-risk patients in advance of anticipated iodide exposure such as elective ICM-based procedures. Further studies are needed to evaluate the safety and effectiveness of this approach.

Consistent with prior findings, we also observed that ICM was associated with incident overt hypothyroidism. Although the mechanism of iodine-induced hypothyroidism (failure to escape from the acute Wolff-Chaikoff effect) has not been fully elucidated, it has been presumed to be due to i) iodine-induced inhibition of the sodium-iodide transporter, or ii) generation of iodolipids and iodolactones that inhibit thyroid peroxidase, and is typically observed in iodine-replete regions. Given the potential long-term effects of untreated hypothyroidism (e.g., diastolic hypertension, dyslipidemia, atherosclerosis, and impaired cardiac contractility and relaxation), patients who may be unable to tolerate hypothyroidism due to underlying cardiovascular disease may benefit from thyroid function monitoring following ICM exposure.

Strengths of our study include the examination of a large number of patients with laboratory data and procedures captured within an integrated electronic health care record system; use of rigorous case criteria in order to establish incident hyper- and hypothyroidism; and adjustment for multiple confounders by matching. However, several limitations of our study bear mention. First, this study examined patients from an iodine-sufficient region, and therefore results may not be generalizable to...
patients residing in iodine-deficient areas. Second, patients were required to have ≥2 TSH measurements to ascertain incident thyroid functional disease, and may thus have had a higher underlying likelihood of developing hyper- or hypothyroidism. Although this may limit generalizability, it is unlikely to have influenced internal validity given that this criterion non-differentially applied to cases and controls. Third, due to infrequent FT4/TT4 measurements, case and control status was ascribed according to TSH only, which may have led to outcome misclassification. However, restriction of thyroid functional testing to the ambulatory setting may have attenuated the risk of misclassification of non-thyroidal illness, and the prevalence of central thyroid functional disease is exceedingly low compared to primary thyroid disease. Fourth, the risk of misclassification of non-thyroidal illness, and the prevalence of central thyroid functional disease is exceedingly low compared to primary thyroid disease. As with all observational studies, our findings do not prove that these associations are causal.

Conclusions

In conclusion, our findings indicate that ICM exposure is associated with incident hyperthyroidism and incident overt hypothyroidism in a broadly generalizable community-based population. Given the high prevalence of procedures employing ICM in contemporary medical practice and the adverse cardiovascular sequelae of thyroid functional disease, further studies are needed to determine the risk factors for iodine-induced thyroid functional disease, underlying mechanisms, and safe, cost-effective interventions that may reduce this risk.

References

1. Burman KD, Wartofsky L. Iodine effects on the thyroid gland: biochemical and clinical aspects. Rev Endocr Metab Disord 2000;1:19-25.

2. Leung AM, Braverman LE. Iodine-induced thyroid dysfunction. Curr Opin Endocrinol Diabetes Obes 2012;19:414-9.

3. Burgi H. Iodine excess. Best Pract Res Clin Endocrinol Metab 2010;24:107-15.

4. Katzberg RW, Haller C. Contrast-induced nephrotoxicity: clinical landscape. Kidney Int Suppl 2006:S3-7.

5. van der Molen AJ, Thomesen HS, Morcos SK. Effect of iodinated contrast media on thyroid function in adults. Eur Radiol 2004;14:902-7.

6. Rhee CM, Bhan I, Alexander EK, Brunelli SM. Association between iodinated contrast media exposure and incident hyperthyroidism and hypothyroidism. Arch Intern Med 2012;172:153-9.

7. Semel ME, Bader AM, Marston A, et al. Measuring the range of services clinicians are responsible for in ambulatory practice. J Eval Clin Pract 2012;18:404-8.

8. Chan KA, Platt R. Harvard pilgrim health care/Harvard vanguard medical associates. In: Strom BL, ed. Pharmacoepidemiology. 3rd ed. West Sussex, England: John Wiley and Sons; 2000. pp 285-293.

9. Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 2010;304:1365-74.

10. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. New Engl J Med 1994;331:1249-52.

11. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12.

12. Martins MC, Lima N, Knobel M, Medeiros-Neto G. Natural course of iodine-induced thyrotoxicosis (Jodbasedow) in endemic goiter area: a 5 year follow-up. J Endocrinol Invest 1989;12:239-44.

13. Roti E, Uberti ED. Iodine excess and hyperthyroidism. Thyroid 2001;11:493-500.

14. Thomesen HS, Faber J. Iodine-based contrast media cause hyperthyroidism - another important adverse reaction to contrast media? Acta Radiol 2012;53:1079-80.

15. Vagenakis AG, Wang CA, Burger A, et al. Iodide-induced thyrotoxicosis in Boston. New Engl J Med 1972;287:523-7.

16. Burch HB. Overview of the clinical manifestations of thyrotoxicosis. In: Braverman LE, Utiger RD, eds. Werner and Ingbår’s the thyroid: a fundamental and clinical text. 10th ed. Philadelphia, PA: Lippincott, Williams, and Wilkins; 2013. pp 434-440.

17. Biondi B. How could we improve the increased cardiovascular mortality in patients with overt and subclinical hyperthyroidism? Eur J Endocrinol 2012;167:295-9.

18. Collet TH, Gussekloo J, Bauer DC, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 2012;172:799-809.

19. Nolte, Muller R, Siggelkow H, et al. Prophylactic application of thyrostatic drugs during excessive iodine exposure in euthyroid patients with thyroid autonomy: a randomized study. Eur J Endocrinol 1996;134:337-41.

20. Pearce EN. Iodine-induced thyroid dysfunction: comment on association between iodinated contrast media exposure and incident hyperthyroidism and hypothyroidism. Arch Intern Med 2012;172:159-61.

21. Dugrillon A. Iodolactones and iodoaldehydes--mediators of iodine in thyroid autoregulation. Exp Clin Endocrinol Diabetes 1996;104(Suppl 4):41-5.

22. Markou K, Georgopoulos N, Kyriazopoulou V, Vagenakis AG. Iodide-Induced hypothyroidism. Thyroid 2001;11:501-10.

23. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. New Engl J Med 2001;344:501-9.

24. Martino E, Bartalena L, Pinchera A. Central hypothyroidism. In: Braverman L, Utiger RD, eds. Werner and Ingbár’s the thyroid: a fundamental and clinical text. 8th ed. Philadelphia, PA: Lippincott, Williams, and Wilkins; 2005. pp 762-773.